Show results for
Refine by
Applications
- Solution for Clinical Trials
- Solution for Access to Investigational Medicines
- Actionable Molecular Diagnostic System for Physicians
- Diagnostic Solutions for Lung Cancer
- Liquid Biopsy Solutions for Breast Cancer
- Diagnostic Solutions for Colorectal Cancer
- Radioactive Drugs for Diagnostics
- Radioactive Drugs for Therapeutics
Tumor Specificity Equipment & Supplies In Iran
38 equipment items found
Manufactured by:Mol Scientific based in, CHINA
Mol Scientific offer high-quality Tumor-specific antigenic peptide 2 product(MPE0005199). Mol Scientific committed to bring our esteemed customers high quality products and the finest services at highly competitive prices. ...
Manufactured by:Mol Scientific based in, CHINA
Mol Scientific offer high-quality Tumor-specific antigenic peptide 1 product(MPE0003074). Mol Scientific committed to bring our esteemed customers high quality products and the finest services at highly competitive prices. ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while simultaneously enhancing immune modulation through the conditional activity of a natural immunomodulatory ...
Manufactured by:Treos Bio Limited based inLondon, UNITED KINGDOM
Off-the-shelf products contain 6-12 shared tumor-specific antigen derived peptides optimized for a population. They are personalized with a candidate companion diagnostic test (CDx). In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
Azymetric™ is the best-in-class platform for therapeutic antibodies that can simultaneously bind to multiple distinct locations on a target or to multiple targets, resulting in unique mechanisms of action not accessible through typical monospecific antibodies. Azymetric™ bispecific antibodies can block multiple signaling pathways, recruit immune cells to tumors, ...
Manufactured by:Histo-Line Laboratories based inPantigliate (MI), ITALY
Species Reactivity: Human, Mouse, and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this antibody does not react with CLIP (aa 17-39 of ACTH). Anti-ACTH is a useful marker in classification of pituitary ...
Manufactured by:Histo-Line Laboratories based inPantigliate (MI), ITALY
Species Reactivity: Human, Mouse, and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this antibody does not react with CLIP (aa 17-39 of ACTH). Anti-ACTH is a useful marker in classification of pituitary ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
By combining bi-valency with bi-specificity in the tetravalent format, the dual checkpoint molecule utilizes avidity and bi-specificity to improve anti-cancer immune cell function. The specificity enhancement both synergistically enhance and expand the breadth of immune cell activity that is diminished in cancer patients (SEBA). The ...
Manufactured by:Nuclidium AG based inBasel, SWITZERLAND
Nuclidium AG leverages the unique properties of copper radionuclides to advance precision radiotherapy and diagnostics. Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating diagnostic and therapeutic pairs designed to optimize the safety and efficacy profile in cancer treatment. These radionuclides, including ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
BRAF mutations are present in multiple types of cancer, including 40% in melanoma, 9% in colorectal cancer (CRC), and 2% in lung cancer. High levels of BRAF protein expression in these tumors suggest susceptibility to T cells targeting the mutation.3 Previous research has shown a durable complete response through transfer of tumor-infiltrating lymphocytes ...
by:Metaclipse Therapeutics Corporation based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a patient’s tumor tissue that Metaclipse modifies with a ‘protein ...
Manufactured by:Jubilant Therapeutics Inc. based inBedminster, NEW JERSEY (USA)
Strong scientific and clinical rationale for novel small molecule PRMT5 ...
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
Tumors with specific FGFR aberrations: Solid tumors, Gastric cancer, Myelolymphoid neoplasms PHASE ...
Manufactured by:APC Cardiovascular Ltd. based inHartford, UNITED KINGDOM
EmboCept® S DSM 50 µm is certified for chemoembolization of inoperable liver and lung tumours ...
Manufactured by:Radiopharm Theranostics based inCarlton, AUSTRALIA
PTPµ (PTPmu) is a peptide molecule biomarker, invented by Dr Susann Brady-Kalnay at Case Western Reserve University in Ohio. ...
by:DEARGEN Inc. based inDaejeon, SOUTH KOREA
ADC (Antibody-drug conjugate) is a next-generation antibody-drug conjugate that has improved efficacy over existing antibodies. This drug combines the advantages of two factors: target specificity, which is a characteristic of an antibody, and cytotoxicity, which is a characteristic of a drug. Specifically, this is a technology focused on targeting and killing ...
by:Onegene Biotechnology based inSuwon, SOUTH KOREA
OGB23501 is a first-in-class tri-specific tumor microenvironment (TME) immune activator, which simultaneously targets PD-1, CTLA-4, and VEGF. We aim to develop it as a potential backbone therapy for melanoma, NSCLC, HCC, and renal ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
nfP2X7 is a tumour-specific form of the P2X7 ligand-gated ion channel, consisting of three identical protein subunits. When exposed to high concentrations of extracellular adenosine triphosphate (ATP), P2X7 forms a channel, driving a range of diverse physiological functions including proliferation and immune cell functions. Under prolonged stimulation, P2X7 can form a membrane pore that’s ...
by:Myeloid Therapeutics based inCambridge, MASSACHUSETTS (USA)
Myeloid is focused on advancing its ATAK CAR monocytes, which are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. Additionally, Myeloid has streamlined manufacturing for its ATAK cell therapy candidates through a rapid, single-day cell process. This method provides significant advantages to the patient, contract development, and manufacturing organizations ...
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
4-1BB mAb-based, tumor antigen targeting bispecific ...